ASAnna Magdalena Sigmund

Anna Magdalena Sigmund

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Magdalena Sigmund has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Desmosomal Hyper-Adhesion Affects Direct Inhibition of Desmoglein Interactions in Pemphigus

    by Letyfee Steinert, Michael Fuchs, Anna M. Sigmund, Dario Didona, Christoph Hudemann, Christian Möbs, Michael Hertl, Takashi Hashimoto, Jens Waschke, Franziska Vielmuth


  • Open Access

    EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects against Pemphigus Vulgaris IgG–Induced Acantholysis in Human Epidermis

    by Desalegn Tadesse Egu, Thomas Schmitt, Nancy Ernst, Ralf Joachim Ludwig, Michael Fuchs, Matthias Hiermaier, Sina Moztarzadeh, Carla Sebastià Morón, Enno Schmidt, Vivien Beyersdorfer, et al.


  • Open Access

    cAMP: A master regulator of cadherin‐mediated binding in endothelium, epithelium and myocardium

    by Franziska Vielmuth, Mariya Y. Radeva, Sunil Yeruva, Anna M. Sigmund, Jens Waschke

    Regulation of cadherin‐mediated cell adhesion is crucial not only for maintaining tissue integrity and barrier function in the endothelium and epithelium but also for electromechanical coupling within the myocardium. Therefore, loss of cadherin‐mediated adhesion causes various disorders, including vascular inflammation and desmosome‐related diseases such as the autoimmune blistering skin dermatosis pemphigus and arrhythmogenic cardiomyopathy. Mechanisms regulating cadherin‐mediated binding contribute to the pathogenesis of diseases and may also be used as therapeutic targets. Over the last 30 years, cyclic adenosine 3′,5′‐monophosphate (cAMP) has emerged as one of the master regulators of cell adhesion in endothelium and, more recently, also in epithelial cells as well as in cardiomyocytes. A broad spectrum of experimental models from vascular physiology and cell biology applied by different generations of researchers provided evidence that not only cadherins of endothelial adherens junctions (AJ) but also desmosomal contacts in keratinocytes and the cardiomyocyte intercalated discs are central targets in this scenario. The molecular mechanisms involve protein kinase A‐ and exchange protein directly activated by cAMP‐mediated regulation of Rho family GTPases and S665 phosphorylation of the AJ and desmosome adaptor protein plakoglobin. In line with this, phosphodiesterase 4 inhibitors such as apremilast have been proposed as a therapeutic strategy to stabilize cadherin‐mediated adhesion in pemphigus and may also be effective to treat other disorders where cadherin‐mediated binding is compromised.


  • Open Access

    Author Correction: Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

    by Anna M. Sigmund, Markus Winkler, Sophia Engelmayer, Daniela Kugelmann, Desalegn T. Egu, Letyfee S. Steinert, Michael Fuchs, Matthias Hiermaier, Mariya Y. Radeva, Franziska C. Bayerbach, et al.


  • Open Access

    Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

    by Anna M. Sigmund, Markus Winkler, Sophia Engelmayer, Daniela Kugelmann, Desalegn T. Egu, Letyfee S. Steinert, Michael Fuchs, Matthias Hiermaier, Mariya Y. Radeva, Franziska C. Bayerbach, et al.

    Pemphigus vulgaris is a life-threatening blistering skin disease caused by autoantibodies destabilizing desmosomal adhesion. Current therapies focus on suppression of autoantibody formation and thus treatments directly stabilizing keratinocyte adhesion would fulfill an unmet medical need. We here demonstrate that apremilast, a phosphodiesterase 4 inhibitor used in psoriasis, prevents skin blistering in pemphigus vulgaris. Apremilast abrogates pemphigus autoantibody-induced loss of keratinocyte cohesion in ex-vivo human epidermis, cultured keratinocytes in vitro and in vivo in mice. In parallel, apremilast inhibits keratin retraction as well as desmosome splitting, induces phosphorylation of plakoglobin at serine 665 and desmoplakin assembly into desmosomal plaques. We established a plakoglobin phospho-deficient mouse model that reveals fragile epidermis with altered organization of keratin filaments and desmosomal cadherins. In keratinocytes derived from these mice, intercellular adhesion is impaired and not rescued by apremilast. These data identify an unreported mechanism of desmosome regulation and propose that apremilast stabilizes keratinocyte adhesion and is protective in pemphigus.


  • Open Access

    Apremilast prevents blistering in human epidermis by stabilization of keratinocyte adhesion in pemphigus

    by Anna M. Sigmund, Markus Winkler, Sophia Engelmayer, Desalegn T. Egu, Daniela Kugelmann, Mariya Y. Radeva, Franziska C. Bayerbach, Stefan Kotschi, Sunil Yeruva, Enno Schmidt, et al.

    Pemphigus vulgaris (PV) is a life-threatening blistering skin disease caused by autoantibodies (PV-IgG) destabilizing desmosomal adhesion. Current therapies focus on suppression of autoantibody formation and thus treatments directly stabilizing keratinocyte adhesion would fulfill an unmet medical need. We here demonstrate that apremilast, a phosphodiesterase 4 inhibitor used e.g. in psoriasis, prevents blistering in PV. Apremilast abrogated PV-IgG-induced loss of keratinocyte cohesion in ex-vivo epidermis and in vitro . This was paralleled by inhibition of keratin retraction and desmosome splitting but affected neither desmoglein (Dsg) depletion nor Dsg3 binding properties. Apremilast induced phosphorylation of plakoglobin at serine 665 – a mechanisms which is known to stabilize cardiomyocyte cohesion. Interestingly, keratinocytes phospho-deficient at this side showed altered organization of Dsg1, Dsg3 and keratin filaments and impaired adhesion, which was not rescued by apremilast. These data identified a new mechanism of desmosome regulation and propose that apremilast is protective in pemphigus by stabilizing keratinocyte cohesion.